Kirjoita osake tai kryptovaluutta hakupalkkiin saadaksesi yhteenvedon
Molecular Templates Inc
MTEMMolecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other serious diseases in the United States. The company develops therapies through its proprietary biologic drug platform technology (ETB). It is also developing MT- 8421, an ETB candidate that is in Phase I clinical trial for the treatment of dismantling TME through direct cell-kill of tumor and immune cell; MT-0169, which is in Phase I clinical trial to treat relapsed/refractory multiple myeloma; and MT-6402 in that is in Phase I clinical trial for relapsed/refractory patients with PD-L1 expressing tumors. The company has a collaboration agreement with Bristol Myers Squibb to discover and develop novel products containing ETBs directed to multiple targets. Molecular Templates, Inc. was founded in 2001 and is headquartered in Austin, Texas. Address: 9301 Amberglen Boulevard, Austin, TX, United States, 78729
Analytics
WallStreetin tavoitehinta
18 USDP/E-suhde
–Osinkotuotto
–Kuluva vuosi
Edellinen vuosi
Nykyinen vuosineljännes
Viimeinen vuosineljännes
Kuluva vuosi
Edellinen vuosi
Nykyinen vuosineljännes
Viimeinen vuosineljännes
Avainluvut MTEM
Osinkoanalytiikka MTEM
Osinkojen kasvu 5 vuoden aikana
–Jatkuva kasvu
–Maksusuhde 5 vuoden keskiarvo
–Osinkohistoria MTEM
Osakkeen arvostus MTEM
Talousasiat MTEM
Tuloksia | 2019 | Dynamiikka |